Search Results - "Lheureux S"

Molecularly targeted therapies in cancer: a guide for the nuclear medicine physician.

Authors: Lheureux, S. Denoyelle, C. Ohashi, P. et al.

Source: European Journal of Nuclear Medicine & Molecular Imaging. Aug2017 Supplement 1, Vol. 44, p41-54. 14p. 2 Diagrams.

Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis.

Authors: Poveda, A. Lheureux, S. Colombo, N. et al.

Source: Gynecologic Oncology. Mar2022, Vol. 164 Issue 3, p498-504. 7p.

Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.

Authors: Rodriguez-Freixinos, V. Lheureux, S. Mandilaras, V. et al.

Source: Gynecologic Oncology. May2019, Vol. 153 Issue 2, p304-311. 8p.

631P Phase Ib expansion study of CX-5461 in patients with solid tumours and BRCA2 and/or PALB2 mutation.

Authors: Soberanis Pina, P.D. Lheureux, S. Han, H. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS503-S503. 1p.

Germline BRCA1/2 testing practices in ovarian cancer: Current state and opportunities for new directions.

Authors: Lheureux, S. Karakasis, K. Harter, P. et al.

Source: Gynecologic Oncology. Jan2016, Vol. 140 Issue 1, p90-94. 5p.

A phase I combination dose-escalation study of eribulin mesylate and gemcitabine in patients with advanced solid tumours: a study of the Princess Margaret Consortium.

Authors: Lheureux, S Oza, A M Laurie, S A et al.

Source: British Journal of Cancer. 12/1/2015, Vol. 113 Issue 11, p1534-1540. 7p. 4 Charts, 2 Graphs.

A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: A trial of the Princess Margaret, Chicago and California Phase II Consortia.

Authors: Hirte, H. Lheureux, S. Fleming, G. F. et al.

Source: Gynecologic Oncology. Jul2015, Vol. 138 Issue 1, p55-61. 7p.

8P Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer.

Authors: Lheureux, S. Rosen, E. Lee, E. et al.

Source: Annals of Oncology. 2022 Supplement 1, Vol. 33, pS4-S5. 2p.

531P Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial.

Authors: Poveda Velasco, A.M. Lheureux, S. Colombo, N. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS790-S790. 1p.

Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer.

Authors: Harter, P. Trillsch, F. Okamoto, A. et al.

Source: Annals of Oncology. Apr2026, Vol. 37 Issue 4, p503-520. 18p.

How to assess the potential interest of aspirin in ovarian cancer?

Authors: Lheureux, S Karakasis, K Oza, A M

Source: Cancer Epidemiology. Oct 2015, Vol. 39 Issue 5, p790-791. 2p.

Clinical behavior of low grade serous ovarian carcinoma: An analysis of 714 patients from the Ovarian Cancer Association Consortium (OCAC).

Authors: May, T. Lheureux, S. Bernardini, M.Q. et al.

Source: Gynecologic Oncology. Jun2017 Supplement 1, Vol. 145, p14-14. 1p.

8046 POSTER Clinical Characteristics of Patients With Sporadic or BRCA Mutated Ovarian Cancer

Authors: Lheureux, S. Ruterana, L. Hardouin, A. et al.

Source: European Journal of Cancer. Sep2011 Supplement 1, Vol. 47, pS541-S541. 1p.

Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.

Authors: Lee, Y.C. Milne, R.L. Lheureux, S. et al.

Source: European Journal of Cancer. Oct2017, Vol. 84, p114-120. 7p.

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.

Authors: Pujade-Lauraine, E. Selle, F. Scambia, G. et al.

Source: Annals of Oncology. Dec2023, Vol. 34 Issue 12, p1152-1164. 13p.

815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI).

Authors: Banerjee, S. Leary, A. Lheureux, S. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS768-S768. 1p.

763P Re-VOLVE: Phase II trial in women with ovarian cancer progressing post-PARP-inhibitor with treatment adapted to real-time assessment of evolving genomic resistance.

Authors: Soberanis Pina, P.D. Oza, A.M. Dhani, N. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS577-S578. 2p.

751P Safety and tolerability of durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizumab (B) followed by D, B + olaparib (O) maintenance (mtx) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumour BRCA1/BRCA2 mutation (non-tBRCAm) in the phase III DUO-O trial

Authors: Aghajanian, C. Schmalfeldt, B. Okamoto, A. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS570-S571. 2p.

619MO Camonsertib (cam) monotherapy in patients (pts) with advanced cancers harboring ATM loss-of-function (LoF).

Authors: Carneiro, B.A. Rosen, E. Fontana, E. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS496-S496. 1p.

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Authors: Spreafico, A. Oza, A.M. Clarke, B.A. et al.

Source: Gynecologic Oncology. Feb2017, Vol. 144 Issue 2, p250-255. 6p.